Bruker Corporation

Bruker Corporation(BRKR)股票分析

$54.800

-1.688 (-3.08%)收盤時

Loading chart…
最高
57.180
開盤
56.450
成交量加權均價
55.41
成交量
1.67M
市值
9.72B
最低
54.265
成交金額
92.78M
企業價值/稅息折舊攤銷前利潤(TTM)
17.36

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others.

AI 分析 of Bruker Corporation (BRKR)

持有

Bruker Corp is currently trading at $54.80, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim, indicating potential upside. However, the stock has a low RSI of 26.87, suggesting it is oversold, and a negative 5-day change of -6.87% indicates recent weakness. The main risk is the significant net income loss of $62.9 million reported in Q2 2026, which raises concerns about profitability.

分析師評級(14)

-4.78% 下跌空間
持有
2 買進
10 持有
2 賣出
目前: 54.80
最低
40.00
平均
52.18
最高
60.00

Barclays

2026-10-07

目標價

$70

增持

Guggenheim

2026-10-01

目標價

$72

買進

Leerink

2026-09-29

目標價

$80

優於大盤

UBS

2026-09-09

目標價

$65

中性

TD Cowen

2026-07-15

目標價

$60

持有

估值指標

Bruker Corporation(BRKR)目前預期本益比為 13.83,5 年平均預期本益比為 23.49。

預期本益比

低估
5 年均值 P/E
23.49
目前P/E
13.83
高估
29.59
低估
17.39

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
17.56
目前EV/EBITDA
17.36
高估
21.13
低估
13.98

預期股價營收比

合理
5 年均值 P/S
2.90
目前P/S
2.33
高估
3.81
低估
1.99

Alphio AI 對 BRKR 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BRKR

$53.26

情境價格

基

基準

基準 · 50%BRKR

$44.40

情境價格

悲

悲觀

悲觀 · 25%BRKR

$41.00

情境價格

持有 BRKR 的大戶

E

Edmond de Rothschild Asset Management (France)

+ 持有BRKR

+7.54%

3個月報酬率

B

Becker Capital Management Inc

+ 持有BRKR

+4.53%

3個月報酬率

S

Snyder Capital Management, L.P.

+ 持有BRKR

+4.03%

3個月報酬率

C

Cornerstone Investment Partners, LLC

+ 持有BRKR

+2.63%

3個月報酬率

P

Pallas Capital Advisors LLC

+ 持有BRKR

+0.72%

3個月報酬率

O

Orbis Investment Management Limited

+ 持有BRKR

-0.85%

3個月報酬率

BRKR 常見問題 —— 由 Alphio AI 解答

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bruker Corp is currently trading at $54.80, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim, indicating potential upside. However, the stock has a low RSI of 26.87, suggesting it is oversold, and a negative 5-day change of -6.87% indicates recent weakness. The main risk is the significant net income loss of $62.9 million reported in Q2 2026, which raises concerns about profitability.

14 analysts cover BRKR: 2 rate it Buy, 10 Hold and 2 Sell. The average price target is 52.18.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易